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There are four classified retroviruses that 
infect humans and cause symptomatic 
disease. Human T-cell lymphotropic virus 
(HTLV) types 1 and 2 are members of the 
Deltaretrovirus genus in the subfamily 
Orthoretrovirinae, show a low rate of evolu-
tion in the human population, and probably 
originated from a non-human primate mil-
lions of years ago1–4. The high frequency of 
HTLV-1 infections was localized in specific 
endemic areas (for example, southern Japan) 
until recent times, indicating a relatively slow 
spread in the human population compared 
with another human retrovirus, HIV-1.
HIV-1 was introduced into the human 
population just 60–80 years ago5 but an 
estimated 40 million individuals are cur-
rently infected with the virus6. The spread 
and expansion of HIV-1 across Africa and 
throughout the world has been accompanied 
by one of the most rapid evolutionary rates 
described for a human pathogen6, aside from 
hepatitis C virus. HIV-1 remains one of the 
most lethal pathogens (100% mortality) that 
currently infects humans, whereas infection 
by other human viruses that are often more 
feared, such as Ebola, severe acute respiratory 
syndrome (SARS), influenza H5NI and Lassa 
Fever, can have a mortality rate of <50% 
(REFS 7–9).
Whether or not a lethal pathogen evolves 
to become a relatively benign parasite or 
even a commensal organism has been a 
subject of great debate. The survival of 
Euroasian populations during the European 
bubonic plague (1347–1352) and the 1918 
influenza epidemic is often perceived as 
evidence for pathogen attenuation. However, 
neither Yersinia pestis nor the H1N1 influ-
enza virus seem to have attenuated during 
these relatively short human epidemics. 
Surviving the Y. pestis epidemic is thought 
to be more related to fractionation of the 
human population, the resistance of rodent 
ectoparasites and, possibly, the selection of 
resistant human hosts10,11.
Nonetheless, there are many examples 
of microparasite evolution and host selec-
tion leading to attenuation or resistance 
to disease. The best documented and 
controlled example is the rapid outgrowth 
of an attenuated myxoma virus following 
its introduction into Australia in 1950 to 
control the expanding rabbit population12–14. 
This virus might have attenuated as a result 
of altered immunomodulatory properties 
in addition to a reduction in the replication 
rate13,14. More recent analyses of archived 
reports from the fifteenth century suggest 
that the dramatic decrease in the severity 
of syphilis symptoms that took place over 
a period of less than 10 years was related to a 
reduction in virulence rather than the selec-
tion of resistant hosts15. Rapid (decades to 
centuries) versus slow (thousand to millions 
of years) attenuation might be related to the 
severity of disease, the rate of lethality and 
the transmission efficiency or transmission 
routes. The suggestion that the simian lenti-
viruses have attenuated in their non-human 
primate hosts during millions of years 
of co-evolution16 has been challenged by 
recent phylogenetic analyses that indicate 
the introduction of simian immunodefi-
ciency virus (SIV) into African primates 
might be a relatively recent event that 
unfolded in the past hundreds or thousands 
of years, therefore indicating that primate 
lentiviruses might frequently jump between 
primate species and then rapidly adapt to 
the new host17,18.
Studies that have modelled the expan-
sion and contraction of various epidemics 
have indicated that the inter-relationships 
between lethal pathogens and their hosts are 
complex and frequently not comparable19–22. 
These questions can only be answered by 
understanding pathogen evolution, dynam-
ics and spread within the population at large 
and within infected hosts. The propensity 
for HIV-1 to evolve rapidly in response to 
various immune and other host pressures 
indicates that this virus is more likely to 
become attenuated through a reduction of 
virulence rather than selection of resistant 
hosts.
Defining pathogen fitness and virulence
The phylogenetic approaches that are com-
monly used to describe the evolution of 
pathogens do not examine how these genetic 
differences actually impact on the physical 
attributes, often termed the fitness, of the 
pathogen. This is understandable, given the 
complexities of measuring fitness, which can 
be defined as the adaptability or reproduc-
tive success of an organism in a specific 
environment. In the case of HIV-1 research, 
fitness is frequently misrepresented or over-
interpreted23,24. For example, HIV-1 virions 
in which the reverse transcriptase (RT) 
harbours mutations that confer resistance 
to antiretroviral drugs (ARVs) such as 3TC 
(Lamivudine or Epivir) seem less fit than vir-
ions carrying the wild-type RT25,26. However, 
this reduced fitness in a reconstituted 
in vitro assay does not necessarily imply that 
the drug-resistant virus will be less fit in a 
human host receiving ARVs. Fitness in each 
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environment can be inter-related but is not 
necessarily consequential. For the purposes 
of this Opinion article, HIV-1 fitness will be 
defined in a specific environment and only 
significant correlations between environ-
ments will be highlighted as being potentially 
consequential.
Fitness is not always synonymous with 
virulence, which is typically defined as the 
rate of host mortality as a consequence 
of infection27 but which can be further 
refined to include the reproduction rate 
and pathogenic potential of the pathogen28. 
These parameters also define the fitness of a 
pathogen within a host. Typically, virulence 
is difficult to measure for viruses such as 
HIV-1, given the long asymptomatic period 
after infection. Therefore, intermittent 
measures of HIV-1 replicative fitness during 
disease can often provide insights into the 
rates of disease progression29–32. Confusion 
between these principles of virulence and 
fitness is introduced when examining fitness 
within the host compared with examining 
fitness within a population24,33. Maynard, 
Ewald, Anderson, May, Novak and oth-
ers22,33–36 suggest that pathogen strain ‘A’, with 
slow replicative fitness but high transmission 
efficiency, will be favoured in a host popula-
tion over strain ‘B’, with increased replicative 
fitness. However, when the strains compete 
together in a single host, it is clear that strain 
‘B’ is more virulent and would out-compete 
and, consequently, be fitter than, strain ‘A’. 
In terms of a pathogen spreading through 
a host population, high pathogen fitness is 
then defined by a reduction in reproduction 
rate and virulence without a loss in trans-
mission. This article will address the possible 
direct relationship between HIV-1 virulence 
and replicative fitness but it is important 
to note that attenuation of virulence is not 
always synonymous with lower replicative 
capacity. For example, the attenuation of 
myxoma virulence in the Australian rabbit 
population might be more related to changes 
in virus-mediated immunomodulation than 
to lower replicative fitness in rabbits13,14.
Expansion of HIV-1 in humans
HIV-1 was first introduced into the human 
population from the chimpanzee subspecies 
Pan troglodytes troglodytes37–39. Most recently, 
Keele et al. have discovered a region in south-
ern Cameroon where chimpanzees carry 
SIV strains (SIVcpzptt) that are closely related 
to two distinct lineages of HIV-1, the main 
(M) and new (N) groups37 (FIG. 1). The origin 
of the outlier (O) group might be related to a 
jump from Gorilla gorilla40. SIVcpzptt was intro-
duced into the human population multiple 
times, over decades to possibly centuries, 
but these transfer events probably started to 
increase in the 1920s to the 1950s as a result 
of human migration into this dense tropical 
region5,37–39. Similar to the pending introduc-
tion of influenza H5N1 from the avian to 
the human host41, a distinct but possibly rare 
SIVcpzptt strain might have had the capacity 
for efficient replication and sexual transmis-
sion in humans17,37. Following this founder 
event, human population density and contact 
had to be sufficiently high for subsequent 
transmission and spread. It is possible that 
a single transmission of HIV-1 group M 
spawned the >60–80 million infections that 
have taken place since the beginning of the 
epidemic37. By contrast, HIV-2 originated in 
humans from a cross-species transmission 
from sooty mangabeys in west Africa (near 
or in Guinea-Bissau) around 1930–1955 
(REFS 42,43). In the 1980s, the incidence of 
HIV-1 group M in central Africa and HIV-2 
in west Africa expanded exponentially but 
clearly at different rates, as the prevalence of 
HIV-1 M infections (28 million) far exceeds 
that of HIV-2 infections (<1 million)6,44,45. 
In stark contrast, HIV-1 groups O and N 
are responsible for <25,000 infections, most 
of which are in Cameroon and Gabon6,46–49. 
The expansion and divergent evolution of 
HIV-1 group M into diverse subtypes (FIG. 1) 
has been dated to 1956–1976 and might have 
coincided with human emigration and the 
seeding of new regional epidemics in central 
Africa5,50,51.
HIV-1 subtypes share 70–90% sequence 
identity, groups share <70%, and HIV-1 
and HIV-2 can differ as much as 50% at the 
nucleotide level (FIG. 1). Given this extreme 
genetic diversity, is it reasonable to assume 
that not all HIV types, groups, subtypes 
and even isolates have evolved to maintain 
similar virulence? Although many research 
articles have described genotypic differences 
between subtypes, there are only a handful 
of studies that have examined potential 
phenotypic differences among the human 
lenti viruses52–56. No studies have modelled 
how phenotypic or ‘fitness’ differences 
among these viruses might affect disease 
progression in infected individuals or the 
general spread of the virus in the human 
population. This article can only provide 
predictions of temporal HIV-1 attenuation 
based on published studies and significant 
trends during the human epidemic. To 
understand how attenuation of virulence 
can occur, it is important to understand the 
population dynamics and fitness of HIV-1 in 
each infected host and during host-to-host 
transmission.
How HIV-1 infects, and evolves in, a host
In relation to other sexually transmitted 
pathogens, HIV-1 is transmitted with 
moderate efficiency by sexual contact and 
apparently greater efficiency by direct 
blood-to-blood contact (for example, needle 
sharing by intravenous drug users)57,58 or 
vertical mother-to-child perinatal transmis-
sion59. There are many cases of discordant 
couples in which the HIV-positive individual 
fails to transmit the virus to the uninfected 
partner despite frequent opportunity60. A 
schematic of transmission events and disease 
progression is provided in FIG. 2 and BOX 1. 
An increased viral load in the donor and con-
sequently in the inoculating dose increases 
the transmission efficiency61,62. An increased 
viral load in the donor also corresponds 
to greater genetic diversity of the inoculat-
ing HIV-1 population (termed the virus 
isolate)63 (FIG. 2), and yet few HIV-1 clones 
will establish an infection in the recipient64. 
This dramatic bottleneck might be related 
to accessing the initial target cells (cells of 
the dendritic lineage)65,66 and establishing 
a productive, systemic infection. Based on 
extensive studies on RNA viruses, it is clear 
that restrictive genetic bottlenecks invoked 
by various selection pressures will reduce 
replicative fitness67–69. Unfortunately, nearly 
all of these viral fitness studies have been 
done in tissue-culture infections and not in 
animal models or in defined donor–recipient 
transmission pairs. Greater HIV-1 genetic 
diversity during acute or early infection has 
been associated with more rapid disease pro-
gression70. In addition, the genetic diversity 
of HIV-1 seems to correlate directly with 
replicative fitness29.
HIV is the obvious aetiological agent of 
AIDS, yet it is commonly assumed that the 
phenotypic characteristics and replication 
efficiency (the ex vivo fitness) of the infect-
ing, wild-type HIV isolates have little impact 
on the rate of disease progression. Much 
attention has been focused on host correlates 
of disease progression, such as the strength of 
HIV-specific immune responses71–77 and host 
genetic polymorphisms that might affect HIV-
1 replication78–82. RNA load remains the best 
predictor of HIV disease progression83 and 
the dramatic reductions in this load achieved 
by ARV treatment can delay disease progres-
sion84. It is important to note that a high viral 
load is not an absolute in relation to the sever-
ity of the disease. In non-human hosts such as 
sooty mangabeys, a high SIV load is not asso-
ciated with clinical symptoms85. Recent stud-
ies indicate that the decline in CD4+ T-cell 
counts, and not the increase in viral load, is a 
better predictor of disease progression86.
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Figure 1 | Phylogenetic tree of human and simian lentiviruses. The 
genetic similarity between different HIV and simian immunodeficiency 
virus (SIV) strains was compared by aligning the full genome sequences of 
87 human and simian lentiviruses using ClustalX v.1.83 (the accession 
numbers are available on request). Phylogenetic trees based on nucleotide 
distance were constructed by neighbour-joining methods as implemented 
in ClustalX with 1,000 bootstrap resamplings (not presented) and sche-
matically represented with the TreeView program. HIV-2 and HIV-1 share 
only 50–60% sequence identity and cluster at distinct locations on the 
phylogenetic tree whereas SIVcpz branches out from the root of the HIV-1 
groups. The origins of these HIV-1 groups in southern Cameroon have 
recently been described and indicate two probable jumps from chimpan-
zee (groups M and N) and gorilla (group O) species. HIV-1 M subtypes prob-
ably evolved from a discrete introduction into the human population and 
then diverged into different subtypes. The subtypes defined as ‘A-like’ 
describe HIV-1 isolates with sequences that map phylogenetically more to 
subtype A than to any other subtype. For example, the recombinant form 
CRF02_AG (such as 02 AG.NG.IBNG in the HIV-1 group M A-like cluster) 
has longer genomic segments that are more related to subtype A than to 
subtype G. M, main; N, new.
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The first evidence that specific viral 
genetic traits might affect virulence was the 
identification of long-term non-progressing 
individuals harbouring a defective HIV-1 
isolate lacking a nef open reading frame87,88. 
Mutations or deletions in this accessory-
protein-coding gene can significantly 
impair fitness in tissue-culture infections89. 
Even with this discovery 10 years ago, the 
effect of relative HIV-1 replicative fitness 
on disease progression has not been the 
subject of intense study owing to difficulties 
in accurately measuring HIV-1 fitness.
There have been only limited studies 
examining how virus fitness changes during 
natural infections31,32,90,91. The replication 
capacities of different HIV-1 isolates are 
commonly compared by measuring ex vivo 
growth kinetics in single virus infec-
tions31,32. The viruses used in many studies 
are not isolated from infected patients but 
rather are chimeric recombinant viruses 
containing gene(s) from the patient’s virus 
within the genome of a laboratory HIV-1 
strain32,92. Small environmental differences 
in separate single virus infections and the 
inherent variability of detection assays can 
prevent accurate estimates of viral fitness 
by these methods. By contrast, dual virus 
infections or competition assays involve 
multiple rounds of virus replication, are less 
affected by environmental changes and, as 
a result, can quantify small but significant 
differences in fitness29,93,94. In HIV research, 
multiple and single-cycle single virus 
infections, and competition experiments, 
have been used in studies that described 
impaired HIV-1 replicative fitness con-
ferred by drug-resistance mutations95,96. 
Nevertheless, the impact of these drug 
resistance mutations in primary HIV-1 
isolates (as opposed to chimeric viruses) 
has not been fully assessed.
Initial reports using HIV-1 competition 
assays in peripheral blood mononuclear 
cell (PBMC) cultures to measure fitness 
indicated that many long-term survivors 
harbour HIV-1 with an impaired replication 
capacity, whereas rapid progressors can 
be infected with more aggressive HIV-1 
isolates30. Subsequent studies indicated 
that the genetic diversity and fitness of the 
intra-patient HIV-1 population continues 
to increase during disease and to diverge 
from the founder HIV-1 clones29,63,70 (FIG. 2). 
This diversity reaches an inflection point 
just before the inception of AIDS symptoms. 
During the asymptomatic period, the steady 
increase in HIV-1 diversity occurs concomi-
tantly with increasing viral load and, more 
significantly, with increasing ex vivo replica-
tive fitness of the infecting HIV-1 isolate29 
(FIG. 2). Red Queen dynamics (in which the 
interaction between a parasite and its host 
leads to a constant evolutionary process of 
adaptation and counter-adaptation) predict 
that increasing replicative fitness must be 
associated with a continual expansion of the 
genetic breadth and size of a population97,98. 
Any strong selective pressure can result in the 
contraction of population size, the appear-
ance of deleterious mutations and decreasing 
fitness99–101. Interestingly, the introduction of 
ARVs as a strong selective pressure during 
asymptomatic disease resulted in a dramatic 
decrease in HIV-1 load, genetic diversity 
and replicative fitness, even in the absence of 
drug resistance mutations29.
Following transmission, it is possible that 
the replicative fitness and genetic diversity 
of newly infecting HIV-1 isolates is lower 
than that of the inoculating virus from the 
donor (BOX 1). Such a continual increase 
in HIV-1 diversity and fitness is in direct 
conflict with the idea that the HIV-specific 
acquired immune response can counter this 
viral expansion102. Discrepancies in these 
data might simply be due to the time period 
of sampling and analyses. HIV-1 genetic 
diversity and fitness only increases after the 
first one to two years of infection29 (FIG. 2). 
Immediately following acute infection, 
both host genetics and the HIV-specific 
immune response might have crucial roles 
in establishing a genetic diversity and fitness 
set point, which might also correspond with 
the well-documented viral-load set point83,103 
(FIG. 2). Cell-mediated immunity could be the 
most dominant factor in specifically reducing 
viral load and, as a consequence, fitness and 
diversity104–107.
How can HIV-1 virulence be attenuated?
The genes at the human leukocyte antigen 
(HLA) loci are extremely variable. In 
humans in most geographical regions, it 
is typically rare to find a perfect match in 
the HLA A–G alleles that encode major 
histocompatibility complex (MHC) class I 
and in the six HLA D genes that encode 
MHC class II. Even in regions of specific 
ethnicities, there is considerable population 
diversity in HLA alleles, which encompass 
at least 21 major A, 35 B and 15 C alleles 
(see the dbMHC web site). Compared with 
Eurasian populations, HLA diversity is 
much greater in the main ethnic groups of 
sub-Saharan Africa; a study of >4,000 indi-
viduals characterized at the A, B and C loci 
found no preference for a single allele108. 
The least HLA diversity is often observed in 
more homogeneous Caucasian populations, 
most notably, the Caucasian Australian 
population (see the dbMHC web site)109.
How might a human population that is 
diverse in terms of HLA type or other host 
polymorphisms influence HIV-1 evolution? 
Figure 2 | A hypothetical example of changes in replicative fitness and viral load during HIV-1 
disease progression. An individual is typically infected by a few HIV-1 clones (depicted by a small 
green circle), which dramatically increase in copy number but not in genetic diversity during the first 
1–2 months of infection. Following this acute infection period, viral load is reduced partly as a result of 
strong HIV-specific cell-mediated immunity. The virus population is thought to oscillate between expan-
sion of HIV-1 populations owing to immune escape from existing HIV-specific cytotoxic T-lymphocyte 
(CTL) clones and contraction caused by new genetic bottlenecks that are induced by newly emerging 
CTL clones. The replicative fitness and genetic diversity of the HIV-1 population seem to track closely 
together and, following early disease (purple box), both increase at a relatively linear rate with the 
length of infection. This increase in replicative fitness correlates with increases in viral loads (right axis) 
and decreases in CD4+ T-cell counts (not shown). The scale for replicative fitness is arbitrary but is 
derived from the relative HIV-1 fitness values, that is, the ability of one HIV-1 isolate to out-compete 
another in ex vivo dual-virus competition experiments.
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Quantitative aspects of the HIV-specific 
immune response (for example, high levels 
of HIV-specific cytotoxic T lymphocytes 
(CTLs) versus low levels) are self-limiting 
because this immunity is not transferred 
between individuals. However, a qualitative 
difference in terms of what the immune 
system ‘sees’ in the infecting HIV-1 strain 
could have a significant impact on viru-
lence. A mismatch of HLA genes between 
the donor and recipient of a transmission 
pair would result in the presentation of a 
different set of HIV-1 peptide epitopes to 
CD8+ T cells in the recipient that were not 
recognized in the donor110,111. With each 
new transmission, the infecting virus must 
then evolve to escape this pressure, which in 
turn seems to reduce replicative fitness112,113. 
In human populations with a low HLA 
diversity (for example, in Australia), CTL 
escape mutations might become fixed along 
with compensatory mutations that restore 
or maintain HIV-1 virulence109 (BOX 1). By 
contrast, the constant passage of HIV-1 
through humans of different HLA types 
(for example, in Africa) might prevent the 
accumulation of compensatory mutations, 
which could stabilize CTL escape muta-
tions (BOX 1). However, a model involving 
only HLA types is obviously too simplistic, 
considering the effects of other host factors. 
For example, polymorphisms in other host 
restriction factors, such as ABOBEC3G/3F 
and TRIM5α, could also alter disease 
progression114,115. Furthermore, host poly-
morphisms in the HIV-1 co-receptor CCR5 
and its ligands (for example, CCL3L1) alter 
co-receptor or ligand expression levels and, 
as such, affect the ability of HIV-1 to use 
the co-receptor78–82. If these polymorphisms 
exist at high frequencies in the human 
population, they too could result in an oscil-
lation between HIV-1 sequences that, in 
this example, reduce or increase co-receptor 
avidity, a correlate of replicative fitness.
In general, HIV-1 virulence might attenu-
ate if, on average, the loss in fitness that 
occurs following transmission is greater than 
the gain in replicative fitness that occurs 
during asymptomatic disease progression 
(BOX 1). Loss of fitness is probably due to 
the genetic bottleneck during transmission 
and/or escape from host restrictions or the 
host immune response during early disease. 
The continual introduction of new selective 
pressures and genetic bottlenecks would 
lead to the accumulation of deleterious 
mutations, which in turn would reduce rep-
licative fitness or virulence. However, these 
hypotheses have not been empirically tested 
using HIV-1 transmission pairs.
Box 1 | A model for HIV-1 attenuation
The figure shows a model for HIV-1 attenuation in a human population with diverse and limited 
genetic polymorphisms that are associated with HIV-1 disease progression. In this illustration, 
patient A is the founder who will infect patient B approximately 4 years into the infection of A. 
Before transmission from patient A to patient B, the replicative (or pathogenic) fitness of the virus 
has increased from 4 to 7 (arbitrary units, see FIG. 2 legend). Although the replicative fitness 
increases in patient A, the transmission from patient A to patient B results in a genetic bottleneck 
that resets the fitness to a lower baseline or set level (dotted line). As patients A and B are not an 
HLA match, the cell-mediated immune response (or CTL response) of patient B recognizes a 
different set of HIV-1 epitopes than in patient A. In patient B, mutations in this new set of epitopes 
are necessary for CTL escape and for the virus to expand in the face of this anti-viral response. 
However, this ‘escape’ from the CTL response comes at a fitness cost and reduces the replicative 
fitness in the first 1–2 years of infection. Following this escape, the infecting HIV-1 isolates seem to 
continually increase in number (that is, the viral load increases)83 and gain replicative fitness29 
(FIG. 2). This process is repeated with each transmission event in patients with diverse HLA alleles.
Patient B transmits to patient C and patient C transmits to patient D during acute infection. 
Increased transmission efficiency is associated with higher viral loads, which are highest during 
acute infection. However, the short time interval of acute infection provides limited opportunity for 
transmission. As the disease progresses and viral load increases, the efficiency of transmission will 
increase even though opportunities for transmission can remain constant. Consequently, more 
transmission events might result from prolonged, compared with rapid, disease progression (for 
example, transmission from patient D to E) even when accounting for the high transmission 
efficiencies during acute infection149,150. In this model, owing to the fitness bottlenecks at 
transmission and the subsequent loss in fitness caused by CTL escape111–113, the circulating HIV-1 
isolate will start to lose virulence. This loss in virulence would decrease pathogenesis, prolong the 
time to AIDS or even result in a non-symptomatic infection. The complete clearance of HIV-1 is 
unlikely because of the stable integration of the provirus into memory T cells with long half lives 
and possible re-activation of virus replication in these cells160,161.
In patients with limited genetic diversity and possible HLA matches, loss of fitness might be 
associated with the genetic bottleneck following transmission but the infecting HIV-1 isolate could 
be more ‘resistant’ to the breadth of possible CTL responses. For example, patient A transmits HIV-1 
to patient X 1.5 years into the infection. After 1.5 years, the HIV-1 isolate in patient A has mutated 
the dominant HIV-1 epitopes and escaped CTL activity. When patient A infects patient X (who is a 
match at some or all of the HLA alleles), the virus from patient A cannot be efficiently recognized by 
the CTL response of patient X and so could result in a more rapid disease progression. An HIV-1 
isolate passing through patients of limited HLA diversity might actually increase in virulence. 
CTL, cytotoxic T lymphocyte; HLA, human leukocyte antigen.
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HIV-201_AE 02_AG
03_AB
06_cpx
12_BF
08 or 07_BC
Unique recombinant forms (URF)
Circulating recombinant formsDominant subtypes Minor subtypes
Subtype B
Subtype A1
Subtype C
Subtype F1
Subtype D
Subtype G
Subtype A3
Subtype A2
Subtype F2
Subtype J
Subtype H
North and Central America, Carribean
South America
Europe
West Africa
Central Africa
Horn of Africa
North Asia
Central Asia
 South Asia
Southern Africa
Total HIV-1 infected
36,000,000
C 52%
B 10%
A1 12%
URF 4.2%
02 6.7%
01 3.1%
G 5%
D 3.6%
Is there evidence for attenuation of HIV-1?
With the exceptions of anecdotes, a 
few case reports and one published study 
on a large cohort, there is no evidence 
that HIV-1 virulence has either increased 
or decreased during the past 20–30 years 
of the pandemic116–121. One of the main 
obstacles in comparing disease progres-
sion in the mid-1980s with the current 
day epidemic in the developed world is 
the significant medical advancements that 
have been made. In the developing world, 
until recently, few if any cohorts have 
been analysed for disease progression. 
Finally, owing to increased awareness and 
education about AIDS, patients are now 
diagnosed earlier, sometimes during acute 
infection, whereas in the 1980s many 
patients did not present to a clinic until 
the onset of AIDS. As a result, there is 
often the impression that HIV-1 infections 
are less aggressive now than they were at 
the beginning of the pandemic.
In a study published last year, >100 
primary HIV-1 isolates were obtained from 
patient samples in Antwerp, Belgium, but 
only twelve could be matched from the 
periods 1985–1987 and 2002–2003 (REF. 121). 
All 24 viruses from both time periods were 
competed against each other in PBMC from 
HIV-negative donors. Based on >500 head-
to-head virus competition experiments, the 
recent HIV-1 isolates were significantly less 
fit than the historical isolates121. These find-
ings indicate that HIV-1 might have attenu-
ated in replicative fitness over the past 15–18 
years. If the fitness of the infecting HIV-1 
strain is a predictor of disease progres-
sion29–32, reduced ex vivo fitness in PBMC 
might be a strong correlate of decreased 
virulence. However, these results should be 
interpreted with caution owing to the lim-
ited sample size involved. Furthermore, the 
cross-sectional design of this study results in 
sampling of HIV-1 isolates at a single time 
point during disease progression, which was 
controlled for disease stage based on CD4+ 
T-cell count and viral load. Nonetheless, the 
increased fitness of the 1980 viruses versus 
the 2000 viruses was significant and greater 
than any increase in HIV-1 fitness observed 
during disease progression29,121. Future stud-
ies on large cohorts that span the epidemic 
temporally in various geographical regions 
are warranted but, as described below, these 
studies will again be limited to analyses of 
HIV-1 virulence (that is, replicative fitness) 
as rates of disease progression will not be 
available (see below).
Rates of disease progression have now 
been examined in a European HIV-infected 
cohort spanning the years 1986–2002 
(REF. 119). The slopes of CD4+ T-cell decline 
were calculated in antiretroviral-treatment-
naive patients with confirmed dates of infec-
tion, at no fewer than nine time points over 
periods >1 year. Following this early period 
of the AIDS epidemic, there seems to be 
some evidence for slowing rates of disease 
Figure 3 | HIV-1 diversity in the worldwide epidemic. The frequency 
of each HIV-1 subtype and recombinant form was estimated in each 
country based on published findings. A complete breakdown of sub-
type prevalence per country and the countries present in each 
region are listed in the Supplementary information S1 (table). The 
countries are colour-coded based on the dominant HIV-1 group main 
(M) subtype. The countries coloured grey have a low level of HIV-1 
prevalence or were not represented in the scientific literature related 
to HIV-1 subtype prevalence. The pie charts depict the proportion of 
each subtype or recombinant form in each geographical region. The 
size of the pies is proportional to the number of HIV-1 infected indi-
viduals in that particular region.
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progression from 1992–1998. Interestingly, 
the period following 1992 also corresponds 
to increasing use of combination ARV 
treatment, which could only be indirectly 
related to this attenuation as none of the 
patients received ARVs during the study 
period. It is possible that drug resistance 
mutations might have appeared at a higher 
frequency during sub-optimal treatment 
from 1992–1998, that is, before the wide-
spread use of highly active antiretroviral 
therapy (HAART). These mutations have 
been associated with reduced fitness95,96 but 
their presence following a new transmission 
and in the absence of ARV treatment is low 
(<5–20%)122,123 and would not fully explain 
why the rates of disease progression might 
have decreased between 1992–1998.
The detection of fluctuations in the rate 
of CD4+ T-cell decline at the start of the 
HIV-1 epidemic in Europe is surprising 
given the preliminary data suggesting that 
replicative fitness might have been higher in 
the 1980s compared with the 2000s (REF. 121). 
Slopes of CD4+ T-cell decline can be heavily 
influenced by the length of longitudinal fol-
low-up, the follow-up period post-infection, 
and the number of data points124. For exam-
ple, most patients in the 1980s presented 
to a clinic with advanced disease when the 
slopes of CD4+ T-cell decline are commonly 
lower than in early disease (especially 
once the level falls below 200 CD4+ T cells 
per µl)124,125. Therefore, ‘slow’ disease pro-
gression during 1986–1988 might be associ-
ated with the accrual of patients with more 
advanced disease. In general, natural history 
cohorts starting at early or acute infection 
and ending with AIDS-defining illnesses 
or morbidity (typically 3–10 years without 
ARV treatment) provide the best estimates 
of CD4+ T-cell decline and disease progres-
sion rates125. In the developed world, cohorts 
from the 1980s are not readily available 
owing to late diagnosis, whereas the current 
cohorts are difficult to assess for the natural 
history of disease due to ARV intervention. 
Finally, given the reduced HLA diversity and 
greater ethnic homogeneity in the Caucasian 
population, the attenuation rate of subtype B 
HIV-1 virulence might be less dramatic than 
the attenuation possible with non-B subtypes 
in sub-Saharan Africa.
In vivo and ex vivo fitness differences
Early observations on the rates of disease 
progression in west Africa showed that 
HIV-2 infections were less aggressive than 
HIV-1 infections126,127. HIV-2 is also trans-
mitted less frequently than HIV-1 in human 
populations of similar demographics and 
similar opportunities for sexual contacts128,129. 
Whereas HIV-1 has spread across the globe, 
founder events of HIV-2 in areas other than 
west Africa did not result in regional epidem-
ics (FIG. 3). Even HIV-1 infections are not 
evenly distributed among the different groups 
and subtypes: group N infections have only 
been characterized in five Cameroonians, 
whereas ~30,000 group O infections are 
estimated in Cameroon and Gabon6,46.
HIV-1 group M subtype C has spread 
more rapidly than any other M subtype, partly 
as a result of recent subtype C pandemics in 
southern Africa, south America and Asia130–133 
(FIGS 3,4a; Supplementary information S1 
(table)). ‘Pure’ HIV-1 subtype C or HIV-1 
recombinant forms containing at least 
the envelope gene of subtype C are now 
responsible for >50% of the HIV-1 infections 
worldwide130. A founder event of subtype C 
or a C-containing recombinant form in 
many regions has also resulted in an apparent 
displacement of existing HIV-1 subtypes 
(such as subtypes B and CRF01_AE in south 
China131,132, many subtypes in Kinshasa, 
Democratic Republic of Congo134 and 
subtype B in southern Brazil133) (FIGS 3,4a). This 
displacement could be due to the introduction 
of subtype C into a population by different 
transmission routes (heterosexual transmission 
versus intravenous drug use) or increased 
sexual activity (for example, commercial sex 
workers)135. A subtype might initially predomi-
nate in a specific transmission group but there 
is little supporting evidence to suggest that sub-
types A, B, C, D and CRF01_AE (also referred 
to as E) are any more or less transmissible by 
a specific route, in a specific ethnic group or 
in specific cell types53,136–141. In addition, such 
initial predominance is generally lost during 
an epidemic. For example, in Thailand HIV-1 
subtypes B and CRF01_AE were segregated 
to intravenous drug users and heterosexuals, 
respectively, in the late 1980s but are now more 
uniformly mixed in the Thai population142.
Recent studies have attempted to 
establish the ex vivo ‘pathogenic’ and 
‘transmission’ fitness of different HIV types, 
groups and subtypes52. Ex vivo ‘pathogenic 
fitness’ has been previously described as 
the relative replication capacity of HIV-1 
in primary blood cells (CD4+ T cells and 
PBMCs), which in turn, might be related 
to HIV-1 virulence30,53. By contrast, ex vivo 
‘transmission fitness’ is measured by com-
peting primary HIV-1 isolates in cells of the 
dendritic lineage, which are derived from 
blood monocytes or human skin53,143. Future 
dual HIV-1 competition experiments using 
vaginal or cervical biopsy explants might be 
the best model for transmission fitness65,66. 
To first establish the ‘pathogenic fitness’ (or 
virulence) of HIV, pair-wise competitions 
were done with eight HIV-2, six HIV-1 
group O and 15 HIV-1 group M isolates 
(2 subtype A, 5 subtype B, 4 subtype C, 
2 subtype D and 2 subtype CRF01_AE) in 
PBMCs144 (FIG. 4b). These viruses were clas-
sified as using either the CCR5 (R5) or the 
CXCR4 (X4) co-receptor for entry. When 
HIV isolates of the same phenotype (X4 or 
R5) were competed against each other, the 
following fitness order (based on >2,000 
competitions) was observed (FIG. 4b): HIV-1 
group M (subtype A, B, D and CRF01_AE) 
had a greater fitness than subtype C, which 
in turn was greater than HIV-2, and HIV-1 
group O showed the lowest fitness.
With the exception of subtype C, this 
order reflects the prevalence of these human 
lentiviruses in the human population and 
the proposed rates of transmission effi-
ciency128,129. The R5 HIV-1 subtype C isolates 
were at least 100-fold less fit than HIV-1 
isolates of any other group M subtype53. 
Aside from subtype C, no other HIV-1 
subtype has shown a significant fitness dif-
ference in group M53,144. Subtype C HIV-1 
isolates are preferentially CCR5-tropic and 
non -syncytium-inducing (NSI) throughout 
disease, whereas infections with HIV-1 iso-
lates of other subtypes result in a switch from 
CCR5 to CXCR4-tropic virus in approxi-
mately 50% of late disease cases. A few rare 
X4 subtype C isolates have been obtained 
from infected Zimbabweans late in disease145 
but even the switch from R5 to X4 did not 
restore fitness, compared with other group M 
isolates (Nankya, I. et al, unpublished data).
What causes differential spread?
Differential spread of human lentiviruses 
in the host population is controlled by both 
transmission efficiency and opportunity, 
which is collectively referred to as R0 (REF. 22). 
Several models of microparasite expansion 
in humans have been proposed20,22,33,146,147 but 
most assume that during the early stages of 
the epidemic, the rate of infection (dY/dt) 
simply increases as a function of the number 
of infected individuals (Y) during an infec-
tious period (v = rate of moving into a non-
infectious state), the probability of infecting 
a new host (β ) and the frequency of sexual 
contact (c) (REF. 22).
dY/dt ~ (βc –v)Y   (1)
The opportunities for HIV-1 transmission 
relate to the number of sexual contacts, which 
are more frequent during acute infection and 
in the asymptomatic period of disease than 
during AIDS. An infected individual (without 
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general knowledge of the transmission routes 
or infection status) could engage in several 
sexual encounters during the acute or early 
phase (approximately 3 months)148, the 
period of highest HIV-1 load61,62. Therefore, 
the exponential growth of HIV-1 infections 
in the early 1980s could have been primarily 
the result of transmission from acutely 
infected men having sex with men or from 
intravenous drug users148–150 (BOX 1). However, 
in heterosexual populations with a reduced 
frequency of sexual contacts, a donor might 
transmit HIV-1 to more recipients during 
a long asymptomatic period (2–5 years) of 
infection, with moderate viral load, than 
during the acute or early infection stage 
(1–3 months), with high viral load. Low 
HIV-1 virulence, which could lead to longer 
asymptomatic periods, could also increase the 
opportunity for transmission (BOX 1).
Similarly, poor fitness of HIV-1 group O 
and HIV-2 compared with HIV-1 group M 
isolates was found when competitions 
were carried out in both PBMCs (ex vivo 
pathogenic fitness) and in dendritic–T-cell 
cultures (ex vivo transmission fitness)144. 
In relation to this ex vivo model, poor 
transmission efficiency has been well docu-
mented for HIV-2 compared with HIV-1 
in the human populations in which both 
circulate128,129. By contrast, subtype C HIV-1 
isolates had similar ex vivo transmission 
fitness53 compared with group M subtype B 
isolates in Langerhans cells even though 
subtype C isolates are at least 100-fold less 
fit in PBMC cultures53. In vivo observations 
indicate that subtype C HIV-1 is transmit-
ted as efficiently as other HIV-1 group M 
isolates in human cohorts135,137 and in rhesus 
macaques, through the use of SIV–HIV env 
chimeric virus (SHIV-MJ4)151. These ex vivo 
and in vivo observations imply that HIV-1 
subtype C is efficiently transmitted but is less 
virulent than other HIV-1 group M isolates.
HIV-2 and HIV-1 groups O and N might 
have had limited expansion in the human 
population due to poor host adaptation and 
transmission efficiencies. By contrast, HIV-1 
group M seems to be more virulent as well 
as more transmissible. Therefore, the pro-
genitor of the HIV-1 group M lineage might 
have been more ‘fit’ for human infection, 
promoting further adaptation through rapid 
evolution and passage through the human 
population. New founder events in segre-
gated human populations in central Africa 
might have led to subsequent divergence 
into subtypes. HIV-1 subtypes probably 
evolved and diverged under similar selection 
pressures, unless infecting a human popula-
tion with distinct genetic polymorphisms 
that had an effect on virulence. Adaptation 
to the human population followed by attenu-
ation of lethal virulence might, however, 
be occurring at different rates for divergent 
HIV-1 clades. If diversity in HLA types has a 
significant role in HIV-1 evolution, subtypes 
predominating in Africa, such as subtype C, 
might attenuate virulence at a faster rate 
than HIV-1 subtype B, which infects the 
Caucasian population of lower HLA diversity 
in the developed world.
Figure 4 | Relationship between the increasing prevalence of HIV-1 
subtype C and its low pathogenic fitness. The prevalence of HIV-1 
subtype C or subtype C-containing recombinant forms has increased in 
proportion to other HIV-1 subtypes in Rio do Sul, Brazil (from 35% in 1996 
to 52% 2002)133, in Kinshasa and Mbuji-Mayi, Democratic Republic of Congo 
(DRC) (from 2.1% and 16.3% in 1997 to 9.7% and 25% in 2002, respectively)134 
and in Yunnan, China (from 5.1% in 1992 to 90% in 2002)162,163. By contrast, 
subtype C is dominant in South Africa164 and did not increase in proportion 
to subtypes A and D or recombinant forms in Kenya165. The number of HIV-1 
cases increased in all of these regional epidemics (except in Kinshasa)6. 
a | The number of HIV-1 infections in specific years is subdivided into sub-
type C (yellow) and non-subtype-C (maroon) HIV-1 infections. b | A sche-
matic representation of the pathogenic fitness of human lentiviruses, 
derived from >3,000 pair-wise dual HIV-1 competition experi-
ments26,27,49,50,108,120,123,125,165. The coloured ovals plot the fitness of primary 
HIV-1 isolates competed against isolates of the same type, group or subtype 
(y axis; mean fitness of 1 or equal fitness) compared with the fitness of pri-
mary HIV-1 isolates competed against isolates of different types, groups or 
subtypes. Each oval encompasses the fitness (x and y fitness values) of at 
least 10 to 20 primary HIV-1 isolates. M, main; O, other.
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Prevalence and reduced virulence
HIV-1 subtype C might be in a more 
advanced stage of attenuation than other 
HIV-1 subtypes53,96,144. If it is less virulent 
than other subtypes, subtype C infections 
might result in slower disease progression, 
longer periods of asymptomatic infection and 
more opportunities for transmission; that 
is, it would be associated with an increase 
in R0 (see equation [1]; BOX 1). To support 
a model of disproportionate expansion of 
HIV-1 subtype C in the human population 
(FIGS 3,4a), the transmission efficiency of sub-
type C must be greater than, or comparable 
to, other HIV-1 group M strains. Preliminary 
data suggest that subtype C is transmit-
ted as efficiently as other HIV-1 group M 
subtypes53,135,137,151. Therefore, decreased 
virulence could have a key role in the spread 
of subtype C by increasing the opportunity 
for transmission33. So far, comparisons of 
cohorts infected with subtype C and other 
subtypes show similar or higher viral loads 
in the subtype C-infected individuals152,153. 
These initial observations would argue 
against the possible subtype C attenua-
tion and would support the more popular 
assumption, that subtype C is more virulent. 
However, there are few studies on the 
natural history and progression of patients 
infected by any HIV-1 subtype other than 
subtype B154–157. Two studies have described 
faster disease progression in individuals 
infected with subtype D compared with 
subtype A- or subtype C-infected individuals 
in Uganda and Tanzania154–156. The possibil-
ity of greater subtype D virulence has been 
attributed to a higher propensity to switch 
from the NSI/R5 phenotype to the more 
aggressive syncytium-inducing (SI)/X4 
phenotype158. By contrast, subtype C rarely 
switches from the NSI/R5 to the SI/X4 
phenotype. At a recent presentation at the 
sixteenth International AIDS Conference 
in Toronto, Canada159, interim analyses of 
disease progression were described in a 
cohort of 256 subtype A-, C- and D-infected 
women, recruited at acute or early infection 
and followed for a mean of 36 months. The 
mean slope of CD4+ T-cell decline in the 
subtype C-infected women from Zimbabwe 
was 2.3-fold slower than in subtype A- and 
D-infected women from Uganda (p<0.008). 
However, there were no differences in the 
mean viral loads at 3 and 12 months between 
the countries or between different subtypes. 
Slower disease progression, as described by 
slower declines in CD4+ T-cell counts, was 
not attributable to any other factors (such as 
opportunistic infections, sexual activity, diet, 
age and weight) apart from being infected 
with subtype C versus subtype A or D. In the 
Bantu corridor extending from Zimbabwe to 
Uganda, the frequency of HLA-A, -B and -C 
alleles and other host polymorphisms (for 
example, CCR5 deletions or promoter poly-
morphisms) are similar and could rule out 
obvious human genetic differences skewing 
HIV-1 evolution108.
Summary
The attenuation of infectious pathogens 
remains contentious and many doubt that 
the spread of HIV-1 through the human 
population will lead to decreased virulence 
as HIV-1 isolates actually gain replicative 
(or pathogenic) fitness during infection of 
human hosts. However, this gain might not 
be sufficient to reverse the loss in pathogenic 
fitness that occurs during transmission and 
early disease. The extreme genetic bottleneck 
following transmission reduces the HIV-1 
population size and diversity by at least 
10,000-fold. In vitro studies indicate that this 
genetic reduction correlates with a significant 
fitness loss. The few HIV-1 clones establishing 
infection must evade the immune system, 
resulting in yet another series of genetic bot-
tlenecks reducing fitness. Therefore, attenua-
tion of virulence might occur if the net fitness 
loss during transmission or early disease is 
greater than the increase in pathogenic fit-
ness during disease progression and between 
transmission events. Greater diversity in 
HLA alleles in African populations compared 
with Caucasian populations might result 
in stronger immune pressure in the human 
population and possibly faster rates of HIV-1 
attenuation. Is the global dominance of 
HIV-1 subtype C related to an attenuation of 
virulence? Does subtype C infection lead to 
slower disease progression and more oppor-
tunities for new transmission events? These 
questions might hold the key to the future of 
the HIV-1 epidemic and could provide a new 
focus for ARV treatment and vaccine design.
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